UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
SAN DIEGO, Oct. 20, 2016 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that it has issued inducement awards to two new non-executive employees.
TRACON issued the awards on October 17, 2016 and October 19, 2016. The inducement awards consist of options to purchase an aggregate of 25,740 shares of the Company's common stock and a restricted stock unit award for an aggregate of 9,750 shares of the Company's common stock, and were granted in accordance with NASDAQ Listing Rule 5635(c)(4) under the TRACON Pharmaceuticals, Inc. 2015 Equity Incentive Plan (the "2015 Plan”). Each option has an exercise price per share equal to the closing price of one TRACON share on the Nasdaq Global Market on the dates of grants. The options vest over four years, with 25% of the option shares vesting on the first anniversary of the date of grant and the remaining 75% of the option shares vesting in monthly installments over the three years thereafter. The options have a ten-year term, and are subject to the terms and conditions of the 2015 Plan and applicable stock option agreement. The restricted stock unit vests over four years, with 25% of the shares vesting on the first four anniversary dates of the date of grant. The restricted stock unit is subject to the terms and conditions of the 2015 Plan and applicable restricted stock unit agreement.
About TRACON
TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
Company Contact: Casey Logan Chief Business Officer (858) 550‐0780 ext. 236 [email protected] Investor Contact: Andrew McDonald LifeSci Advisors LLC 646-597-6987 [email protected]
